Thursday, 17 March 2011
Skillman, NJ (March 17, 2011) - ConvaTec Healthcare, a world-leading developer, manufacturer and marketer of innovative medical technologies for community and hospital care, today announced that, following a review of current conditions in the credit markets, it is postponing the refinancing of its senior secured term loans originally entered into on December 22, 2010.
ConvaTec is a leading developer and marketer of innovative medical technologies. With four key focus areas - Ostomy Care, Wound Therapeutics, Continence and Critical Care, and Infusion Devices - ConvaTec products support healthcare professionals from the hospital to the community health setting. From its operational headquarters in Skillman, New Jersey, the company conducts business in over 100 countries, serving consumers and their health care professionals on six continents.
Certain statements in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements are all statements other than statements of historical facts. Certain of these forward looking statements are identified by terminology such as "aim," "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "guidance," "intend," "may," "plan," "potential," "predict," "projected," "should," or "will" or the negative of such terms or other comparable terminology. Others can be identified from the context in which the statements are made. These statements involve a number of risks and uncertainties. Any forward-looking statements that we make herein and in future reports and statements are not guarantees of future performance, and actual results may differ materially from those in such forward-looking statements as a result of a various factors relating to our strategy, outlook and growth prospects, including our operational financial targets; the expected growth of the markets in which we operate; the competitive environment in which we operate; the economic outlook in general and, in particular, economic conditions in European and U.S. markets; growth in demand for our products, increases in the penetration of our products into their respective markets, reimbursement rates for our products, or similar measures; and our expansion plans, including planned expansion into a growth in emerging markets; our ability to gain necessary regulatory approvals and desirable reimbursement rates for our newly developed products and technologies; and our ability to market and launch attractive new product designs and technologies. All forward-looking statements made in this press release are made as of the date hereof, and the risk that actual results will differ materially from expectations expressed herein will increase with the passage of time. The company undertakes no duty to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
This announcement is being distributed to and is directed only at (i) persons who are outside the United Kingdom or (ii) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") and (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling with Article 49(2) (a) to (d) of the Order (all such persons together being referred to as "relevant persons"). Any investment activity to which this communication relates will only be available to and will only be engaged with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.
This document is an advertisement for purposes of applicable measurers implementing Directive 2003/71/EC.
This announcement is not an offer to sell or the solicitation of an offer to buy the new notes in any jurisdiction in which such an offer, solicitation or sale would be unlawful.